Belimumab blocks the soluble counterpart of B cell activating factor (BAFF; also known as B lymphocyte stimulator, BLyS) and has been used for the treatment of SLE for longer than a decade (14). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.